Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension

この論文にアクセスする

この論文をさがす

著者

    • YANAGISAWA Ryoji
    • Second Department of Internal Medicine, Kyorin University School of Medicine
    • TAGUCHI Hiroki
    • Second Department of Internal Medicine, Kyorin University School of Medicine
    • TAMURA Yuichi
    • Department of Cardiology, Keio University School of Medicine
    • YOSHINO Hideaki
    • Second Department of Internal Medicine, Kyorin University School of Medicine
    • SATOH Toru
    • Second Department of Internal Medicine, Kyorin University School of Medicine

抄録

<b><i>Background:</i></b> Sildenafil has been demonstrated as effective for the treatment of pulmonary arterial hypertension (PAH). The purpose of this study was to investigate the occurrence of clinical events after sildenafil monotreatment as a first-line therapy in patients with PAH over a long-term observation period. <b><i>Methods and Results:</i></b> Sildenafil was administered as a first-line drug to 46 patients with PAH (including 24 patients with idiopathic PAH) during 2003-2010. We investigated subsequent clinical events such as the addition of epoprostenol, hospitalization for right-side heart failure, and death. All the hemodynamic parameters and the 6-min walk distance improved significantly in the enrolled patients as a whole receiving sildenafil treatment; 15 (33%) of the 46 patients required the addition of epoprostenol during follow-up. Kaplan-Meier analysis demonstrated that more than 60% of the patients receiving first-line sildenafil treatment did not require the addition of epoprostenol for a 5-year period. Furthermore, the 5-year survival rate after first-line sildenafil treatment was 81%. Finally, more than 75% of the enrolled patients did not reach the composite endpoint of hospitalization for right-side heart failure and death for a 5-year period. <b><i>Conclusions:</i></b> This study describes the long-term outcome of patients with PAH receiving sildenafil monotreatment as a first-line therapy and suggests that it is a promising therapeutic strategy. (<i>Circ J</i> 2012; <b>76:</b> 1245-1252)<br>

収録刊行物

  • Circulation journal : official journal of the Japanese Circulation Society

    Circulation journal : official journal of the Japanese Circulation Society 76(5), 1245-1252, 2012-04-25

    一般社団法人 日本循環器学会

参考文献:  31件中 1-31件 を表示

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    10030132896
  • NII書誌ID(NCID)
    AA11591968
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13469843
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ